Histone Deacetylase Inhibitors Market on Strong Trajectory, Set to Reach ~USD 2.14 B by 2032; Innovation and Epigenetic Therapies Fuel Growth The global Histone Deacetylase (HDAC) Inhibitors market, valued at approximately USD 1.27 billion in 2024, is projected to expand to around USD 2.14 billion by 2032, driven by rising cancer prevalence and accelerating R&D in epigenetic therapies. Simultaneously, advances in precision medicine, increasing investment, and growing interest in...